Head-to-head · Cost-Efficiency Index
AM Rx vs TeleZen MD
Two GLP-1 programs on the bench, scored on the same six factors. Here's how their real cost of ownership compares — and which one we'd start with.
AM Rx
Cost-first shoppers who want insured shoppers chasing brand-name GLP-1 copays, provided they choose the flat Bundle plan rather than the a-la-carte route whose true monthly cost the site doesn't fully disclose.
Visit AM RxTeleZen MD
Shoppers who want named, checkable prescribers before pricing is disclosed and don't mind starting an intake to see a number.
Visit TeleZen MDThe verdict
AM Rx and TeleZen MD tie on the Cost-Efficiency Index at 42/100, so neither wins outright on the numbers. For most shoppers we'd start with AM Rx (ranked #509, a hair above #516) — Cost-first shoppers who want insured shoppers chasing brand-name GLP-1 copays, provided they choose the flat Bundle plan rather than the a-la-carte route whose true monthly cost the site doesn't fully disclose. But TeleZen MD is a genuine coin-flip alternative here.
Worth knowing either way: our overall #1 pick is CoreAge Rx (Cost-Efficiency Index 94/100 — the top of the ranking). See how it stacks up: CoreAge Rx vs AM Rx.
Factor by factor
Both providers scored on our six Cost-Efficiency Index factors. The stronger side on each row is marked in teal.
Normalized Cost/Month
Price Transparency
Nationwide Access
Formulation Options
Clinical Oversight
Contract Flexibility
Pricing, coverage & formulary
The disclosed facts behind the scores. Lower price wins its row (teal).
| Spec | AM Rx | TeleZen MD |
|---|---|---|
| Cost-Efficiency Index | 42/100 | 42/100 |
| Semaglutide / mo | $297/mo (all doses, bundle, plus a separate fee, compounded) | Not disclosed |
| Tirzepatide / mo | $449/mo (all doses, bundle, compounded) | Not disclosed |
| Semaglutide / yr (modeled) | $3,564 | — |
| Tirzepatide / yr (modeled) | $5,388 | — |
| Coverage | Coverage not published | Coverage not published |
| Oral / sublingual | No | No |
| Brand-name access | Yes | Compounded only |
| Rank here | #509 | #516 |
AM Rx
42/100Where the value is
- Insurance coordination for brand-name Ozempic/Wegovy/Zepbound/Mounjaro, quoting copays 'as little as $25 per month'
- A flat 'Bundle' pricing option ($297 semaglutide / $449 tirzepatide after a discounted first month) avoids the ambiguity of the a-la-carte route's undisclosed ongoing membership fee
- HSA/FSA accepted
The tradeoffs
- The headline 'starting as low as $151/$216 per month' figures require a separate ongoing membership fee that AM Rx's own FAQ never discloses the amount of — unlike sibling site RoenRx, which explicitly states $135/month for the equivalent membership
- No states list is published; the only geographic restriction disclosed is exclusion of government-insurance (Medicare/Medicaid) patients
Regulatory note: the FDA issued a warning letter to FitRX, LLC dba AM RX in June 2026. We still list and link to AM Rx; you should know the letter is on the public record before you decide.
TeleZen MD
42/100Where the value is
- Four named, checkable prescribers listed by name and credential (Dr. James Teet DO, Dr. Ozita Cooper MD, Dr. Michael Wasef MD, Dr. Andrew Sakla DO) — better prescriber transparency than most peers in this batch
- Confirmed legal entity via Terms of Use: Telezen MD, LLC, a Florida limited liability company
- LegitScript certified per the FAQ
The tradeoffs
- No price for semaglutide or tirzepatide is published anywhere on the public site — every pricing page checked (/pricing, /treatments, /weight-loss, /how-it-works, /get-started) either 404'd or showed no dollar figure
- The 'all 50 states' claim is the company's own FAQ statement; the only state-specific text found anywhere on the site (in the Terms of Use) names just four states (FL, CA, TX, KS), so the 50-state claim is not independently confirmed by a published list
Assume any provider we list may compensate us — we may earn a commission, at no cost to you. It never changes the Cost-Efficiency Index. Pricing, states and verification reflect each provider's public disclosures at last review; prices change — confirm on the provider's site. Not medical advice. See our disclosure.